Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Agreement allows AstraZeneca to use TAXIScan technology
February 8th, 2006
Effector Cell Institute, Inc., announced that the company has signed a collaborative research agreement with AstraZeneca. The parties will use Effector Cell's TAXIScan technology with the aim of developing a predictive model for identifying patient populations who will best respond to potential new treatments for chronic obstructive pulmonary disease, asthma, and allergy. Under the 3-year agreement, Effector Cell Institute will receive an up-front payment and a yearly fee for the collaboration in addition to certain commercial rights to diagnostics tests and assays. The specific financial terms of the agreement were not disclosed. ...
Source: Immunotherapy Weekly (2006-02-08)
|
